Semax vs Selank for Cognition: One Reader’s Honest Read of the Russian Literature

A pseudonymous reader walks through what the Russian-language human studies actually say about two intranasal heptapeptides, what the Western literature does not say, and where the gaps are big enough to drive a truck through.

by JoyBoy 12 min read Last reviewed May 2026 🟡 Human Observational (both) Neither FDA approved. Both registered medicines in Russia.

Why I looked into this

Search either of these names and the first ten results are nearly identical seller-driven blog posts that all say the same thing in slightly different words. “Semax boosts BDNF.” “Selank modulates GABA.” Lots of mechanism, very little human data, almost no honest discussion of where the studies came from or how they were run.

I wanted to know what the actual Russian literature says, what it does not say, and how to think about a body of evidence that lives almost entirely outside the journals I usually trust. So I read what I could find in English translation, in PubMed-indexed Russian work, and in the regulatory documents the Russian Ministry of Health has published. This piece is what came out of that.

I have not used either peptide. The opinion section at the end is opinion only, no personal experience.

The two molecules at a glance

These are not the same kind of compound, even though the internet often files them under one interchangeable nootropic bucket.

Semax is a synthetic ACTH(4-7) analog. A heptapeptide engineered from a fragment of adrenocorticotropic hormone, with a proline-glycine-proline tail added to extend its half-life and resist enzymatic breakdown. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s. Registered in Russia for ischemic stroke recovery, optic neuropathy, and a range of cognitive disorders, including pediatric attention and learning indications. The mechanistic story most often told about Semax is modulation of brain-derived neurotrophic factor (BDNF) and a broader neurotrophic and neuroprotective profile. Mechanism is interesting. Mechanism is not efficacy.

Selank is a synthetic tuftsin analog. A heptapeptide engineered from the natural immunopeptide tuftsin, again with a stabilizing tail. Developed at the same institute. Registered in Russia for generalized anxiety disorder and related anxiety conditions. The mechanistic story most often told about Selank is GABAergic modulation, with a calming profile that is supposed to lack the sedation, dependence, and cognitive blunting of benzodiazepines.

Both are administered intranasally in their Russian use. Neither has an FDA-approved formulation. The intranasal route is part of why these compounds traveled at all. Bypass the gut, get a peptide into systemic circulation through nasal mucosa, and you have something that might actually do what oral peptides cannot.

What the human research shows

Where the hype came from

If you have heard of either peptide, you most likely heard about it from one of three places: a biohacker podcast, a research-chemical site’s “education” section, or a Reddit thread. None of those are reading the Russian primary literature. Most are summarizing each other.

The mechanistic stories travel well because they are simple. “Semax raises BDNF” is a one-line claim. “Selank modulates GABA without sedation” is a one-line claim. Both are based on real published work, but the journey from a single mechanism paper to “this peptide will sharpen your focus and lower your anxiety” is a journey nobody on the marketing side wants to slow down for.

Add the intranasal route, the Russian origin (which is read as exotic instead of as a compliance concern), and the absence of FDA approval (which is read as “the FDA hasn’t gotten around to it yet” instead of as “nobody has run the trials that would justify approval”), and you get a product story that sells.

Across the safety record I can find, both compounds appear reasonably well-tolerated in the Russian post-marketing experience. That is not the same as “safe at any quantity, in any form, sourced from anywhere.” It also is not the same as “tested to FDA standards.”

FDA and legal status

The PCAC review of Semax is a meaningful regulatory event, but I want to be clear about what it is and is not. Advisory committee inclusion means the FDA convenes outside experts to discuss whether a substance should be permitted on the 503A bulk drug substances list. It is not approval. It is not endorsement. The output is a non-binding recommendation that informs separate rulemaking. A favorable PCAC vote on Semax for cerebral ischemia would still require a long downstream regulatory process before anything changed at the pharmacy level. As of writing, we do not know how the vote will go.

How to evaluate a source: the safety framework

Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name sellers. I do not link to anyone. I am teaching you how to think about a source so you can have an informed conversation with a clinician.

The wrinkle for these two specifically

The Russian registered versions of Semax and Selank are finished intranasal pharmaceuticals manufactured under Russian regulatory oversight. The gray-market versions sold online in the US are research-grade powders, often handled by amateur preparation in someone’s kitchen, then loaded into nasal sprayers of varying quality. Whatever you think of the Russian regulatory standard, “Russian registered medicine” and “powder shipped under research-use-only labeling” are not the same product. The marketing copy that calls them interchangeable is not telling you the truth.

Cost reality

Cheap is suspicious. The economics of small-batch, small-molecule peptide synthesis include actual costs for raw material, synthesis labor, purification, sterility handling, and testing. A vial that costs less than a fast food meal almost certainly skipped one of those line items, and “skipped sterility” is the most common one. The price gap between gray-market product and licensed pharmacy product is real. The thing you are giving up to get the lower price is also real. There is no free lunch.

Questions worth asking any source

Where is this synthesized? Who is the prescribing clinician of record? What independent third-party testing exists, and can I see the certificate of analysis? What happens if I have a reaction? A real source has answers. A bad one has a “research use only” disclaimer pasted next to use-it-this-way instructions written in the same paragraph.

My honest take

Questions to ask your doctor

If you are considering either peptide, here are the questions I would want answered before walking out of the appointment.

1. Have you read the Russian literature on this peptide, or are you working from English-language secondary summaries? The honest answer matters. A clinician who has only read the marketing has a worse view of the evidence than the one who has read at least the abstracts.
2. Given my situation, is there a registered Russian indication that is even close to my use case? Stroke recovery is a registered Semax indication. Generalized anxiety disorder is a registered Selank indication. “Healthy adult who wants more focus” is neither.
3. What is your stop condition? Under what circumstance would you discontinue, what side effects would prompt that, and how long do you plan to keep this going if it does seem to help?
4. Are we discussing the Russian registered medicine, a US compounded version, or a gray-market research-use-only powder? The legal, safety, and clinical questions are different for each. A clinician who lumps those together is not paying attention.
5. What is your view on the PCAC review of Semax in July 2026? A clinician following the regulatory landscape will know what is on the docket and what an advisory committee vote actually means. One who does not is working with old information.
6. What independent third-party testing have you seen for the specific product on offer? If the answer is “the source sends a certificate,” that is not independent. Independent means a separate lab the source did not pay for the result.

What to do next

Sources

• Gusev EI, Skvortsova VI, et al. Semax in acute ischemic stroke: clinical studies in the Russian Federation. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. Multiple publications across the 2000s and 2010s. Funding: largely Russian state and institutional, including Institute of Molecular Genetics RAS.
• Maslova MV, et al. Semax in pediatric attention disorders: Russian clinical work. Russian-language journal publications. Funding: institutional.
• Zozulia AA, Neznamov GG, et al. Selank versus medazepam in generalized anxiety disorder: comparative clinical work. Russian-language psychiatric journals. Funding: institutional.
• Russian Ministry of Health. Registration documentation for Semax and Selank as registered medicines, including approved indications and post-marketing safety information.
• US FDA. Notice of Pharmacy Compounding Advisory Committee meeting, docket FDA-2025-N-6895, July 23 to 24, 2026, including Semax review for cerebral ischemia.
• PubMed-indexed mechanistic literature on Semax and BDNF, and on Selank and GABAergic activity. Funding: largely Russian institutional.

Funding for the bulk of this literature is Russian institutional. Industry funding and independent Western funding are both largely absent. Independent replication outside Russia is essentially absent. That is the most important caveat in this article and it is worth saying twice.

Related monographs